MCID: 48X005
MIFTS: 39

48,xyyy

Categories: Fetal diseases, Neuronal diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for 48,xyyy

Summaries for 48,xyyy

NIH Rare Diseases : 52 The following summary is from Orphanet , a European reference portal for information on rare diseases and orphan drugs. Orpha Number: 99329 Definition A rare Y chromosome number anomaly that affects only males and is characterized by mild-moderate developmental delay (especially speech), normal to mild intellectual disability , large, irregular teeth with poor enamel, tall stature and acne. Radioulnar synostosis and clinodactyly have also been associated. Boys generally present normal genitalia, while hypogonadism and infertility is frequently reported in adult males. Visit the Orphanet disease page for more resources.

MalaCards based summary : 48,xyyy, also known as 48,xyyy syndrome, is related to radioulnar synostosis and hypogonadotropic hypogonadism. The drugs Progesterone and Ezetimibe have been mentioned in the context of this disorder. Affiliated tissues include testes, liver and lung, and related phenotypes are hypertelorism and short neck

Related Diseases for 48,xyyy

Diseases related to 48,xyyy via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 radioulnar synostosis 10.2
2 hypogonadotropic hypogonadism 10.2

Symptoms & Phenotypes for 48,xyyy

Human phenotypes related to 48,xyyy:

58 31 (show all 31)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hypertelorism 58 31 hallmark (90%) Very frequent (99-80%) HP:0000316
2 short neck 58 31 hallmark (90%) Very frequent (99-80%) HP:0000470
3 high palate 58 31 hallmark (90%) Very frequent (99-80%) HP:0000218
4 global developmental delay 58 31 hallmark (90%) Very frequent (99-80%) HP:0001263
5 depressed nasal bridge 58 31 hallmark (90%) Very frequent (99-80%) HP:0005280
6 delayed speech and language development 58 31 hallmark (90%) Very frequent (99-80%) HP:0000750
7 pes planus 58 31 hallmark (90%) Very frequent (99-80%) HP:0001763
8 feeding difficulties 58 31 hallmark (90%) Very frequent (99-80%) HP:0011968
9 intellectual disability, mild 58 31 hallmark (90%) Very frequent (99-80%) HP:0001256
10 long philtrum 58 31 hallmark (90%) Very frequent (99-80%) HP:0000343
11 thick lower lip vermilion 58 31 hallmark (90%) Very frequent (99-80%) HP:0000179
12 recurrent upper respiratory tract infections 58 31 hallmark (90%) Very frequent (99-80%) HP:0002788
13 epicanthus 58 31 hallmark (90%) Very frequent (99-80%) HP:0000286
14 acne 58 31 hallmark (90%) Very frequent (99-80%) HP:0001061
15 abnormal dermatoglyphics 58 31 hallmark (90%) Very frequent (99-80%) HP:0007477
16 male hypogonadism 58 31 hallmark (90%) Very frequent (99-80%) HP:0000026
17 aggressive behavior 58 31 hallmark (90%) Very frequent (99-80%) HP:0000718
18 asthma 58 31 hallmark (90%) Very frequent (99-80%) HP:0002099
19 azoospermia 58 31 hallmark (90%) Very frequent (99-80%) HP:0000027
20 impulsivity 58 31 hallmark (90%) Very frequent (99-80%) HP:0100710
21 radioulnar synostosis 58 31 hallmark (90%) Very frequent (99-80%) HP:0002974
22 tall stature 58 31 hallmark (90%) Very frequent (99-80%) HP:0000098
23 abnormal renal morphology 58 31 hallmark (90%) Very frequent (99-80%) HP:0012210
24 primary gonadal insufficiency 58 31 hallmark (90%) Very frequent (99-80%) HP:0008193
25 dislocated radial head 58 31 hallmark (90%) Very frequent (99-80%) HP:0003083
26 hypoplasia of dental enamel 58 31 hallmark (90%) Very frequent (99-80%) HP:0006297
27 low frustration tolerance 58 31 hallmark (90%) Very frequent (99-80%) HP:0000744
28 irregularly spaced teeth 58 31 hallmark (90%) Very frequent (99-80%) HP:0006316
29 intellectual disability 58 Very frequent (99-80%)
30 behavioral abnormality 58 Very frequent (99-80%)
31 abnormality of the foot 58 Very frequent (99-80%)

Drugs & Therapeutics for 48,xyyy

Drugs for 48,xyyy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1659)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
2
Ezetimibe Approved Phase 4 163222-33-1 150311
3
Amantadine Approved Phase 4 768-94-5 2130
4
Cefuroxime Approved Phase 4 55268-75-2 5361202 5479529
5
Digoxin Approved Phase 4 20830-75-5 30322 2724385
6
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
7
Nepafenac Approved, Investigational Phase 4 78281-72-8 151075
8
Fluvoxamine Approved, Investigational Phase 4 54739-18-3 3404 5324346
9
Riociguat Approved Phase 4 625115-55-1
10
Diltiazem Approved, Investigational Phase 4 42399-41-7 39186
11
Lincomycin Approved, Vet_approved Phase 4 154-21-2 656509
12
Fenoldopam Approved Phase 4 67227-56-9, 67227-57-0 3341
13
Eleuthero Approved, Experimental Phase 4
14
Hexetidine Approved, Investigational Phase 4 141-94-6
15
Bosentan Approved, Investigational Phase 4 147536-97-8 104865
16
Eszopiclone Approved, Investigational Phase 4 138729-47-2 969472
17
Trimetazidine Approved, Investigational Phase 4 5011-34-7
18
Adalimumab Approved Phase 4 331731-18-1 16219006
19
Abacavir Approved, Investigational Phase 4 136470-78-5 65140 441300
20
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
21
Donepezil Approved Phase 4 120014-06-4 3152
22
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
23
Zidovudine Approved Phase 4 30516-87-1 35370
24
Nifedipine Approved Phase 4 21829-25-4 4485
25
Saw palmetto Approved, Experimental, Investigational Phase 4
26
Flurbiprofen Approved, Investigational Phase 4 5104-49-4 3394
27
Neomycin Approved, Vet_approved Phase 4 1404-04-2 8378
28
Eplerenone Approved Phase 4 107724-20-9 150310 443872
29
Dalteparin Approved Phase 4 9005-49-6
30
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
31
Octreotide Approved, Investigational Phase 4 83150-76-9 383414 6400441
32
Omalizumab Approved, Investigational Phase 4 242138-07-4
33
Norepinephrine Approved Phase 4 51-41-2 439260
34
Terlipressin Approved, Investigational Phase 4 14636-12-5 72081
35
Pamidronate Approved Phase 4 40391-99-9 4674
36
Saquinavir Approved, Investigational Phase 4 127779-20-8 60787
37
Interferon beta-1a Approved, Investigational Phase 4 145258-61-3 6438354
38
Natalizumab Approved, Investigational Phase 4 189261-10-7
39
Indinavir Approved Phase 4 150378-17-9 5362440
40
Orphenadrine Approved Phase 4 83-98-7 4601
41
Dezocine Approved, Investigational Phase 4 53648-55-8 40841 3033053
42
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
43
Methocarbamol Approved, Vet_approved Phase 4 532-03-6 4107
44
Fosamprenavir Approved Phase 4 226700-79-4 131536
45
Desogestrel Approved Phase 4 54024-22-5 40973
46
Etonogestrel Approved, Investigational Phase 4 54048-10-1 40976 6917715
47
Atorvastatin Approved Phase 4 134523-00-5 60823
48
chloroquine Approved, Investigational, Vet_approved Phase 4 54-05-7 2719
49
Tavaborole Approved, Investigational Phase 4 174671-46-6
50
Nefopam Approved, Investigational Phase 4 13669-70-0

Interventional clinical trials:

(show top 50) (show all 10000)
# Name Status NCT ID Phase Drugs
1 A Prospective, Randomized, Multicenter, Open-label Study Evaluating HBeAg Seroconversion in HBeAg Positive CHB Patients on Treatment With NA Switched to Combined Therapy With Peginterferon Alfa-2a and NA for 48 Weeks Unknown status NCT02474316 Phase 4 Peginterferon alfa-2a;nucleos(t)ide analgoue
2 Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive. Randomized Clinical, Not Masked, Trial Comparing DRVr3TC, ABC3TC (Kivexa) RPV, or EVG COBI FTC TDF (Stribild) for 48 Weeks Unknown status NCT02470650 Phase 4 elvitegravir/cobicistat/emtricitabine/tenofovir;Darunavir;abacavir/lamivudine;Ritonavir;Lamivudine;rilpivirine
3 Emtricitabine for Naive Chinese Pregnant Chronic Hepatitis B Patients Unknown status NCT02327702 Phase 4 Emtricitabine
4 Efficacy and Safety of Shenyankangfu Tablets for Primary Glomerulonephritis—a Multicentre, Prospective, Double-blind, Double-dummy, Randomized Controlled Clinical Trial Unknown status NCT02063100 Phase 4 Shenyankangfu tablets;Losartan potassium 50mg;Shenyankangfu tablets and Losartan potassium 50mg;Shenyankangfu tablets and Losartan potassium 100mg;Losartan potassium 100mg
5 A Multi-center, Open Label, Randomized Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Capsule Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients Unknown status NCT01436539 Phase 4 Adefovir Dipivoxil and polyene phosphatidylcholine;Adefovir Dipivoxil
6 Eplerenone and Aliskiren Research Targeting Hypertensive Patients With Left Ventricular Hypertrophy Unknown status NCT01893788 Phase 4 Aliskiren;Eplerenone
7 A Phase IV Multicenter Study of the Efficacy and Safety of 48-Week Induction Treatment With TRIZIVIR (Abacavir 300 Mg/Lamivudine 150 Mg/Zidovudine 300 Mg Combination Tablet BID) With Efavirenz (600 Mg QD) Followed by 48-Week Randomized, Open-Label, Maintenance Treatment With TRIZIVIR With or Without Efavirenz in HIV-1 Infected Antiretroviral Therapy Naive Subjects Unknown status NCT00011895 Phase 4 Abacavir sulfate, Lamivudine and Zidovudine;Efavirenz
8 The Efficacy and Safety of the Anti Hepatitis B Placenta Transfer Factor Injection in the Treatment of HBeAg Positive Chronic Hepatitis B, Randomized, Double Blind, Placebo Controlled, Multi Center Clinical Trial Unknown status NCT02412319 Phase 4 Anti-HBV placenta transfer factor injection
9 The Effect of Ketamine on Production of Inflammatory Markers in Post Operative Patients in Mulago Hospital: A Randomized Clinical Trial Unknown status NCT01339065 Phase 4 Ketamine
10 Multi-center, Randomized, Open Label, Comparative, Phase IV Study to Evaluate the Efficacy and Safety of a Combination of Mycophenolate Mofetil and Corticosteroid for 48 Weeks in Advanced IgA Nephropathy Unknown status NCT02981212 Phase 4 Mycophenolate Mofetil;ACE inhibitor;Corticosteroid;ARB
11 A Prospective, Randomized, Multicenter, Open-label, Exploratory Study of Utilizing of "Response-Guided-Therapy (RGT)" Strategy on Optimal Nucleoside Analogue (NUC)-Experienced Patients Unknown status NCT02560649 Phase 4 Peginterferon alfa-2a plus Entecavir;Peginterferon alfa-2a plus Lamivudine;Peginterferon alfa-2a plus Adefovir;Peginterferon alfa-2a plus Tenofovir;Entecavir;Lamivudine;Adefovir;Tenofovir disoproxil
12 Efficacies of Entecavir Add on Chronic Hepatitis B Patients With HBV DNA Load ≥1000 Copies/ml After 6 Months Treatment of Peginterferon Alpha 2a Unknown status NCT02368288 Phase 4 entecavir
13 Efficacies of Entecavir Add on HBeAg Negative Chronic Hepatitis B Patients With HBV DNA Load ≥1000 Copies/ml After 3 Months of Peginterferon Alpha 2a Treatment Unknown status NCT02365402 Phase 4 Entecavir
14 Open, Randomized and Multicenter Phase IV Study to Compare the Efficacy and Safety of Two Different Treatments Duration 24 Versus 48 Weeks in Chronic Hepatitis C Genotypes 2 and/or 3 co-Infected HIV-HCV Patients. Unknown status NCT00611819 Phase 4 Peg interferon + Ribavirin;Peg interferon + Ribavirin
15 Prospective, Double-blinded, Randomised, Placebo Controlled Trial of Pre-emptive Analgesia to Prevent Pain Following Sternotomy for Cardiac Surgery. Unknown status NCT01480765 Phase 4 Pregabalin;Ketamine infusion;Placebo capsules;Placebo infusion
16 Sedation of Mechanically Ventilated Critically Ill Patients: Midazolam Versus Dexmedetomidine Unknown status NCT01256866 Phase 4 Dexmedetomidine;Midazolam
17 Prospective Analysis of the Incidence of Ventilator-associated Pneumonia Related to the Humidification System: Heat and Moisture Exchanger Versus Heated Humidification Unknown status NCT01546974 Phase 4
18 Transfer From Methadone to Buprenorphine Maintenance Treatment Using Buprenorphine Patches: A Study on Practicability With Patients Maintained With Daily Dosages Between 60mg and 100mg Methadone. Unknown status NCT00750217 Phase 4 Buprenorphine patch and sublingual tablets
19 Efficacy and Safety of an Initial Regimen Raltegravir (RAL) + Lamivudine/Abacavir Fixed-Dose Combination (3TC/ABC FDC) for 48 Weeks in ART-naïve, HIV/TB Co-Infected Adult Subjects Receiving Rifabutin-containing, 1-line Anti-TB Therapy Unknown status NCT01059422 Phase 4 Raltegravir; Abacavir/Lamivudine
20 A Randomised, Multi-Centre, Open-Label Study in Well-Controlled Treatment-Experienced HIV-Infected Patients to Assess Compliance With a Once-Daily Regimen of Lamivudine, Efavirenz and Didanosine Versus Continuation of Current Anti-Retroviral Regimen Delivered at Least Twice Daily Unknown status NCT00214435 Phase 4 once daily minimum 3-drug regimen of anti-retroviral medications
21 A Randomized Comparison of Two Albumin Administration Schedules for Spontaneous Bacterial Peritonitis Unknown status NCT00761098 Phase 4 Standard Care;Experimental
22 A Single Center, Prospective Phase IV, Open-Label, Randomized Trial Comparing the Efficacy , Tolerability, and Safety of Quadritherapy Regimen (Reiferon Retard® + Ribavirin + Nitazoxanide + Alfacalcidol ( Bon-One ®) ) Versus Triple Therapy Regimen (Reiferon Retard® + Ribavirin + Nitazoxanide) Versus the Standard of Care Regimen(Reiferon Retard® + Ribavirin) in the Treatment of Naïve Chronic Hepatitis- C Among the Egyptian Population. Effectiveness Will be Evaluated Based on Sustained Viral Response (SVR) Unknown status NCT01896609 Phase 4 Bon one in Arm 3;Xerovirinc in Arm 2;Ribavirin in Arm 1
23 A Multicenter, Open-label, Prospective Study to Evaluate Antiviral Efficacy and Safety of Entecavir Plus Tenofovir Combination in Subjects With Multi-drug Resistant Chronic Hepatitis B Virus Infection Unknown status NCT01594905 Phase 4 Entecavir + Tenofovir (MDR group)
24 Post Operative Pain Control Among Intrathecal 0.1 mg Morphine, Femoral Nerve Block, or Periarticular Infiltration of 20 mL of 0.25% Bupivacaine in Patients Post Intramedullary Hip Screw Unknown status NCT01219088 Phase 4 Bupivacaine, morphine
25 A Randomized, Controlled, Open-label, Multicenter Clinical Trial to Evaluate the Addition of PegIFN Alfa-2a to CHB Patients Treated With Nucleot(s)Ides Unknown status NCT02644538 Phase 4 PegIFN alfa-2a
26 Postoperative Analgesia After Thoracotomy Without Thoracic Epidural Analgesia: Continuous Wound Catheter Analgesia Associated With Intravenous Morphine Patient-Controlled-Analgesia (PCA) Unknown status NCT01698203 Phase 4 ropivacaine 0.75% - device : wound catheter Silver™ 19 cm and Easypump™ 400 mL (BBraun);Placebo;ropivacaine 0.2% - device : wound catheter Silver™ 19 cm and Easypump™ 400 mL (BBraun)
27 An Open, Single-Arm, Multi-Center, Phase IV Pilot Study of Treatment of Antiretroviral Naive HIV-1 Infected Patients With Tenofovir Disoproxil Fumarate in Combination With Emtricitabine and Zidovudine Unknown status NCT00199121 Phase 4 Zidovudine (drug)
28 Chlorhexidine Gluconate for Prevention of Ventilator Associated Pneumonia in a Pediatric Intensive Care Unit. Unknown status NCT01883596 Phase 4 0.12% chlorhexidine solution;Placebo
29 Impact of Starting a Dolutegravir-based Regimen on HIV-1 Proviral DNA Reservoir Of Treatment Naïve and Experienced Patients Unknown status NCT02370979 Phase 4
30 Programmatic Implementation of ACTs in Malawi: Safety and Effectiveness of Combination Therapies With Repeated Treatments for Uncomplicated P. Falciparum Malaria Over a Three-year Period Unknown status NCT01038063 Phase 4 Artemether-lumefantrine combination
31 A Phase IV, Open Label, Multi-Center, Study of Maintenance Intravitreous Injections of Macugen (Pegaptanib Sodium) Given Every 6 Weeks for 48 Weeks in Subjects With Subfoveal Neovascular Age-Related Macular Degeneration (AMD) Initially Treated With a Modality Resulting in Maculopathy Improvement Unknown status NCT00354445 Phase 4 pegaptanib sodium (Macugen)
32 Efficacy and Safety of a Hansenula-derived Pegylated Interferon α2a (Reiferon Retard®) in Treatment of Patients With Chronic Hepatitis C Virus Infection: A National Multi-center Phase IV Open Label Non-Randomized Trial Unknown status NCT01649245 Phase 4 Reiferon retard
33 A Clinical Trial of the Effect of Midazolam on the Cerebral Metabolism and Inflammatory Response in Patients With Moderate and Severe Traumatic Brain Injury Unknown status NCT02071407 Phase 4 Midazolam;Placebo
34 Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy: a Multicentre, Double-blind, Double-dummy, Randomized Controlled Trial Unknown status NCT02231125 Phase 4 Losartan;Abelmoschus manihot
35 Neutrophil gElatinase-associated Lipocalin alloWs Intensive treatMent Of cOntrast Induced Nephropathy in Patients With Urgent/Emergency Percutaneous Coronary Intervention Unknown status NCT01491243 Phase 4 Intensive treatment with sodium bicarbonate;Standard treatment with saline infusion
36 A Multi Center, Phase IIIb Study to Evaluate the Efficacy of Response Guided Therapy Using Quantitative HBsAg Measurement in Patient With HBeAg Positive Chronic Hepatitis B: Unknown status NCT01456312 Phase 4 Peginterferon alfa-2a;Entecavir
37 Impact of Pretreatment With Omega 3 Enriched Lipid Emulsion on Early Neurological Complications After Living Donor Liver Transplantation. A Randomized Controlled Trial> Unknown status NCT02544919 Phase 4 SMOF lipid (SMOFLIPID) pre treatment
38 Analysis of Proximal Renal Tubular Function of "Real World" Chronic Hepatitis B (CHB) Patients Who Are Suppressed on TDF and Switched to TAF Unknown status NCT02957994 Phase 4 Tenofovir alafenamide fumarate
39 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4 Lovaza;placebo control
40 Multicenter Prospective Trial to Investigate Accuracy of Ultrasound to Predict Relapse After Discontinuation of Infliximab and Efficacy/Safety of Readministration of Infliximab in Patients With Rheumatoid Arthritis in Low Disease Activity Unknown status NCT02770794 Phase 4 Infliximab
41 Naproxen for Acute Pain After Surgery: A Randomized, Placebo-Controlled Trial Unknown status NCT00615875 Phase 4 naproxen;placebo
42 Effect of Vitamin D Supplementation on Bone Turnover Markers During Tenofovir-Emtricitibine Pre-Exposure Prophylaxis in Men Who Have Sex With Men; A Sub-study of CCTG 595 Unknown status NCT02367599 Phase 4 Vitamin D Supplement
43 Adductor Canal Block Versus Femoral Nerve Block for Analgesia After Anterior Cruciate Ligament Reconstruction Arthroscopically Unknown status NCT02355093 Phase 4 ropivacaine
44 Grazoprevir/Elbasvir for Treatment of Hepatitis C Virus Genotype 4 Post Kidney Transplant Unknown status NCT03359746 Phase 4 Grazoprevir/Elbasvir
45 Cardiovascular Safety Research: Bupivacaine With Vasoconstrictor Versus Ropivacaine in Brachial Plexus Block Unknown status NCT00523289 Phase 4 Bupivacaine;Ropivacaine
46 An Open Label, Randomized, Parallel Design Estimation Pilot Study to Compare the Effectiveness of 36 vs 48 Wks PegIntron Plus Ribavirin Treatment for HCV Patients Without Rapid Virologic Response(RVR) But With Undetectable HCV RNA at wk 8 Unknown status NCT01683786 Phase 4 Pegintron + Riba
47 An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of a Fixed-Dose Combination of Abacavir 600 mg/Lamivudine 300 mg Once-Daily in Combination With Atazanavir 300 mg + Ritonavir 100 mg Once-Daily in Antiretroviral-Naïve HIV-1 Infected Subjects With Continuing Evaluation of Abacavir/Lamivudine Plus Atazanavir 400 mg for Maintenance Over an Additional 48 Weeks Unknown status NCT00426296 Phase 4 atazanavir (Reyataz);ritonavir (Norvir)
48 Antibiotic Prophylaxis in Prosthetic Breast Reconstructions Unknown status NCT02012517 Phase 4 Prolonged antibiotic treatment;Short antibiotic course (standard of care)
49 Mycophenolate Mofetil in Antiretroviral Naïve Patients 2 (MAN2 Study) Unknown status NCT00120419 Phase 4 mycophenol mofetil (MMF, Cellcept®) 500 mg BID
50 A Randomised Trial Comparing Entacavir and Tenofovir in Patients With HBV Decompensated Cirrhosis Unknown status NCT02238860 Phase 4 Entacavir;Tenofovir

Search NIH Clinical Center for 48,xyyy

Genetic Tests for 48,xyyy

Anatomical Context for 48,xyyy

MalaCards organs/tissues related to 48,xyyy:

40
Testes, Liver, Lung, Brain, Kidney, Heart, Breast

Publications for 48,xyyy

Articles related to 48,xyyy:

(show top 50) (show all 30000)
# Title Authors PMID Year
1
Co-existence of OXA-48 and NDM-1 in colistin resistant Pseudomonas aeruginosa ST235. 61
31964275 2020
2
Rapid Identification of OXA-48-like, KPC, NDM, and VIM Carbapenemase-Producing Enterobacteriaceae From Culture: Evaluation of the RESIST-4 O.K.N.V. Multiplex Lateral Flow Assay. 61
31858767 2020
3
Isolation of virulent phages infecting dominant mesophilic aerobic bacteria in cucumber pickle fermentation. 61
31703878 2020
4
Disease detection at the 48-month exit round of the HPV FOCAL cervical cancer screening trial in women per-protocol eligible for routine screening. 61
31245842 2020
5
Short-term safety and effectiveness of sugammadex for surgical patients with end-stage renal disease: a two-centre retrospective study. 61
31721151 2020
6
Cytotoxicity and inflammatory response of different types of provisional restorative materials. 61
31918345 2020
7
Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials. 61
31834000 2020
8
Correction to: A pH-responsive genetic sensor for the dynamic regulation of D-xylonic acid accumulation in Escherichia coli. 61
31950218 2020
9
Neurofibromas of the oral and maxillofacial complex: A 48-year retrospective study. 61
31675118 2020
10
The complex phenotype of spinocerebellar ataxia type 48 in eight unrelated Italian families. 61
31571321 2020
11
Molecular characterization of carbapenem-resistant Klebsiella pneumoniae ST14 and ST512 causing bloodstream infections in ICU and surgery wards of a tertiary university hospital of Verona (northern Italy): co-production of KPC-3, OXA-48, and CTX-M-15 β-lactamases. 61
31924425 2020
12
Dynamic cytotoxicity of ZnO nanoparticles and bulk particles to Escherichia coli: A view from unfixed ZnO particle:Zn2+ ratio. 61
31945654 2020
13
Cytogenotoxic effects of venlafaxine hydrochloride on cultured human peripheral blood lymphocytes. 61
30025480 2020
14
Role of 68Ga-Prostate-Specific Membrane Antigen PET/CT in Disease Assessment in Glioblastoma Within 48 Hours of Surgery. 61
31977462 2020
15
Resveratrol treatment during maturation enhances developmental competence of oocytes after prolonged ovary storage at 4 °C in the domestic cat model. 61
31951984 2020
16
The First 48 Consecutive Patients with 3-Year Symptom Score Follow-Up Post-Prostate Artery Embolization (PAE) at a Single-Centre University Hospital. 61
31797101 2020
17
Tenofovir monotherapy versus tenofovir plus entecavir combination therapy in HBeAg-positive chronic hepatitis patients with partial virological response to entecavir. 61
31609007 2020
18
The influence of time-to-surgery on mortality after a hip fracture. 61
31652349 2020
19
Biological properties of Phoma macrostoma related to non-dermatophyte onychomycosis. 61
31993320 2020
20
The combination therapy of Peginterferonα and entecavir for HBeAg-positive chronic hepatitis B with high HCC risk. 61
31689542 2020
21
Corrigendum to "Immediate efficacy of Gufoni maneuver for horizontal canal benign paroxysmal positional vertigo (HC-BPPV): A meta-analysis" [Auris Nasus Larynx (2020) 48-54]. 61
31311683 2020
22
Individualized Preconditioning for ABO-Incompatible Living-Donor Kidney Transplantation: An Initial Report of 48 Cases from China. 61
32029699 2020
23
Central mfERG amplitude ratio as a predictor for visual outcome of macular hole surgery. 61
31482394 2020
24
Analgesic and antiallodynic activity of novel anticonvulsant agents derived from 3-benzhydryl-pyrrolidine-2,5-dione in mouse models of nociceptive and neuropathic pain. 61
31874144 2020
25
A 48-year-old female with an exophytic nodule in the buccal mucosa. 61
30249538 2020
26
Transmission and evolution of OXA-48-producing Klebsiella pneumoniae ST11 in a single hospital in Taiwan. 61
31665400 2020
27
Long-term edaravone efficacy in amyotrophic lateral sclerosis: Post-hoc analyses of Study 19 (MCI186-19). 61
31621933 2020
28
Temporal Occurrence of Arrhythmic Complications After Alcohol Septal Ablation. 61
31973555 2020
29
Small Nucleolar RNA Host Gene 1 (SNHG1) and Chromosome 2 Open Reading Frame 48 (C2orf48) as Potential Prognostic Signatures for Liver Cancer by Constructing Regulatory Networks. 61
32036380 2020
30
Predicting chronic algal toxicity from 1- to 48-h pulsed exposures to mine site waters using time-averaged concentrations. 61
32036098 2020
31
Effects of a polysaccharide-rich extract derived from Irish-sourced Laminaria digitata on the composition and metabolic activity of the human gut microbiota using an in vitro colonic model. 61
30805695 2020
32
Variation in clinical usefulness of biomarkers of acute kidney injury in young children undergoing cardiac surgery. 61
32023398 2020
33
Effects of Hot Air Treatments on Postharvest Storage of Newhall Navel Orange. 61
32024051 2020
34
[Volume-based haemostasis reserves in blood product free liver transplantations]. 61
32037866 2020
35
Longitudinal analysis of ESBL and carbapenemase carriage among Enterobacterales and Pseudomonas aeruginosa isolates collected in Europe as part of the International Network for Optimal Resistance Monitoring (INFORM) global surveillance programme, 2013-17. 61
32040168 2020
36
Office-Based Weight Loss Counseling Is Ineffective in Liver Transplant Recipients. 61
31440999 2020
37
Use of a Glass Membrane Pumping Emulsification Device Improves Systemic and Tumor Pharmacokinetics in Rabbit VX2 Liver Tumor in Transarterial Chemoembolization. 61
31542274 2020
38
Outcome of short- to medium-term migration analysis of a cementless short stem total hip arthroplasty using EBRA-FCA: a radiological and clinical study. 61
31786645 2020
39
Acute and chronic effects of competition on ankle dorsiflexion ROM in professional football players. 61
31072261 2020
40
Epidemiological and Accounting Analysis of Ground Ambulance Whole Blood Transfusion. 61
31847923 2020
41
Mycoplasma genitalium Antimicrobial Resistance in Community and Sexual Health Clinic Patients, Auckland, New Zealand. 61
31961302 2020
42
The effect of bisphosphosphonates on bone turnover and bone balance in postmenopausal women with osteoporosis: The T-score bone marker approach in the TRIO study. 61
31740343 2020
43
Early Administration of Oseltamivir Within 48 Hours After Onset of Flulike Symptoms Can Reduce the Risk of Influenza B Virus-Associated Pneumonia in Hospitalized Pediatric Patients with Influenza B Virus Infection. 61
31929434 2020
44
Prevalence of viral load suppression, predictors of virological failure and patterns of HIV drug resistance after 12 and 48 months on first-line antiretroviral therapy: a national cross-sectional survey in Uganda. 61
32025714 2020
45
Correction: Highly efficient room-temperature phosphorescence achieved by gadolinium complexes. 61
31967159 2020
46
Changes in Bone Mass After Discontinuation of Preexposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine in Young Men Who Have Sex With Men: Extension Phase Results of Adolescent Trials Network Protocols 110 and 113. 61
31179503 2020
47
Time to rethink endpoints for new clinical trials of antiretrovirals? Long-term re-suppression of HIV RNA with integrase inhibitors. 61
31876594 2020
48
The Role of Sleep Duration and Sleep Problems During Childhood in the Development of ADHD in Adolescence: Findings From a Population-Based Birth Cohort. 61
31617436 2020
49
Developmental toxicity in embryo-larval zebrafish (Danio rerio) exposed to strobilurin fungicides (azoxystrobin and pyraclostrobin). 61
31600620 2020
50
Cytotoxicity of Ear Drop Excipients in Human and Mouse Tympanic Membrane Fibroblasts. 61
31791190 2020

Variations for 48,xyyy

Expression for 48,xyyy

Search GEO for disease gene expression data for 48,xyyy.

Pathways for 48,xyyy

GO Terms for 48,xyyy

Sources for 48,xyyy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....